KIR2DS2+ NK Cells Show Potential in HCC and Leukemia Treatment
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ex vivo expansion needed for NK cell–based therapies, such as chimeric antigen receptor–NK cell treatment.
Refinements to European Strategy Can Improve PAH-CHD Stratification
When patients were re-classified based on the adjusted thresholds of N-terminal pro-brain natriuretic peptide and 6-minute walk distance and the inclusion of TAPSE rather than right atria area, classification of patients improved significantly.
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Zanubrutinib Not Cost-Effective in China Against Fixed-Duration R-Bendamustine in 1L CLL
The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% in order to be cost-effective compared with bendamustine-rituximab (R-bendamustine) for these patients.
SC Efgartigimod Shows Noninferiority to IV Formulation in gMG
The researchers have detailed their complete findings of subcutaneous (SC) vs intravenous (IV) efgartigimod in generalized myasthenia gravis (gMG) from the phase 3 ADAPT-SC trial and initial findings from the open-label extension of the study, ADAPT-SC+.
Comorbidities Require Special Treatment Consideration for PAH
In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses challenges to the optimal treatment of PAH, explained the researchers.
Mutational Score May Improve Risk Stratification of Certain Patients With AML
The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years or older receiving lower intensity treatment (LIT), including the adoption of a mutation score that accounts for certain gene mutations.
Key Considerations for Optimizing B-VEC in Dystrophic Epidermolysis Bullosa
Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and nails that is caused by mutations in the COL7A1 gene.
Certain Low-Prevalence Mutations May Be Strong Drivers in Pediatric ALL
The researchers noted that most genomic analyses have traditionally focused on commonly mutated genes, which can pinpoint mutations occurring most frequently but does not account for the extent to which these mutations impact cancer cell survival and proliferation.